The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
about
Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiencyMolecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa.Proton pump inhibitor for non-erosive reflux disease: a meta-analysis.GENE EXPRESSION PROFILING OF HUMAN LIVER CARCINOMA (HepG2) CELLS EXPOSED TO THE MARINE TOXIN OKADAIC ACID.Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" ProblemCytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.Pharmacogenetics and human genetic polymorphisms.Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer.Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Analysis of CYP3A4 genetic polymorphisms in Han Chinese.CYP3A variation, premenopausal estrone levels, and breast cancer risk.Potentially immunogenic proteins expressed similarly in human embryonic stem cells and induced pluripotent stem cells.Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism.Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.Multiple inductive effects of carbamazepine on combined therapy with paliperidone and amlodipine.A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms.
P2860
Q24609157-68CBA598-8648-4D7D-A313-1B64EAB26BE5Q34704763-6D6C83B2-D156-4E3C-90E9-1A2C0D2B3061Q35074278-068C1609-9937-4A7F-BD58-79D2608B5FD5Q36406547-97500AC4-B5FE-46B5-99DA-668033688655Q36634077-51A31670-EB51-4948-BA26-993EB54702B5Q36696957-0EC62EA2-405B-42DB-9C21-F020A1376778Q37772183-A2CDD48E-05AC-4125-90BD-AC3830155429Q37818297-10981073-23AB-4DED-AD6D-651490F71C9DQ38086777-037E17F8-6D16-4DE9-BA09-8A8ED5113A88Q38091317-8E1D65BD-40E1-46E9-BD52-773FC5DEC481Q38851505-DF9E047B-1513-4AD5-A1B0-453D7863C8EAQ39575083-2D20EFB0-1DAD-4A9B-BA48-D4AE041470DFQ44288178-6E41A8D5-D288-45F1-ABE2-495E750FE206Q45200161-1438A042-29A3-4ECA-9609-C333B34F677FQ45279289-536482EE-1893-4FA7-AD0C-4F90B022368DQ45916609-62123EB3-D8A7-4E6F-9F0A-9E75806CA9CBQ51021997-B181CF5B-FCA2-4C66-B96E-AA8531D78509Q51141937-482D99EC-5B29-4A36-8BDB-DF604B6D02AC
P2860
The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
@en
The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
@nl
type
label
The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
@en
The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
@nl
prefLabel
The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
@en
The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
@nl
P2860
P1476
The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
@en
P2093
Minoli A Perera
P2860
P356
10.1517/17425250903379546
P407
P577
2010-01-01T00:00:00Z